🔥HOT TOPIC in #HepatologyCommunications Blood-based biomarker screening represents a transformative advance in liver cancer surveillance. Read the full study here: https://bit.ly/4bBmDFX

Alex from our time working together, while he was in nursing school. Later, he moved to ICU, working as a nurse to support critically ill Veterans. He had such a great attitude. We’d chat between patients about trying to get in a mountain bike ride together. Will never happen now

Alex Pretti was a colleague at the VA. We hired him to recruit for our trial. He became an ICU nurse- I lover working with him. He was a good kind person who lived to help and these fuckers executed him. White. Hot. Rage.

We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life Just before his died, he officially earned his doctorate and became Dr. Neumann → myarchoan.wixsite.com/yarchoanlabs...

Celebrating excellence in hepatology! 🌟 We proudly recognized this year’s awardees and honorees at the #TLM25 Awards & Honors Gala. Join us in congratulating this incredible group of 2025 AASLD Distinguished Awardees! 👏👏

BCLC strategy for prognosis prediction and treatment recommendations: The 2025 update If you take care of patients with #HCC, do not miss this new update from BCLC #liversky @easlnews.bsky.social www.journal-of-hepatology.eu/article/S016....

What did the largest trial of an early detection of cancer blood test show? erictopol.substack.com/p/the-larges...

Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25 Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC #ESMOAmbassadors @myesmo.bsky.social

CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC #ESMO25 #ESMOAmbassadors @myesmo.bsky.social

Congratulations to AASLD’s newly elected 2026 SIG Steering Committee Leadership! Your enthusiasm, participation, and commitment to shaping AASLD were seen throughout the election process. Learn more: https://www.aasld.org/2026-aasld-special-interest-group-sig-election-results

Withdrawing from the War on Cancer: an extraordinarily successful scientific research system that took decades to build, saved millions of lives and generated billions of dollars in profits is being dismantled in short order. @jonathanmahler.bsky.social www.nytimes.com/2025/09/14/m...

We are thrilled to announce the #AASLD 2025 Distinguished Award recipients! Join us in celebrating their achievements and commitment to #hepatology. Learn more about each recipient and their remarkable work: https://bit.ly/4giq0SS

A very comprehensive review on current state of HCC screening, diagnosis and treatment. www.jhep-reports.eu/article/S258... #Liversky @easlnews.bsky.social

BREAKING: Gov. JB Pritzker says the Trump administration has sent the Texas National Guard to Great Lakes Naval Base outside Chicago, awaiting orders to deploy to Chicago. Trump administration officials will target Mexican Independence Day (Sept. 16) celebrations. @wttw.bsky.social

The @fda.gov just approved @novonordisk.bsky.social #wegovy on an accelerated path for #MASH F2/F3 fibrosis We now have 2 approved drugs with different MOA and that’s great news for patients. I anticipate at least 5 more approvals in the next 5 years. #liversky

🖤 With deep sorrow, we announce the passing of Prof. Dr. Jaime Bosch, President of the Baveno Cooperation. A brilliant scientist, inspiring leader, and dear friend. His immense legacy in hepatology will endure. Rest in peace, Jaime

THIS IS HUGE! TWO Phase I HIV vaccine clinical trials have demonstrated that a stepwise mRNA-based vaccination strategy can SUCCESSFULLY activate AND advance immune responses toward producing broadly neutralizing antibodies (bnAbs), a CRITICAL milestone in HIV prevention. Let’s talk about that! 🧪🧵⬇️

We've greatly underestimated the role of the gut microbiome in fatty liver disease (MASLD). This open-access outstanding review @jclinical-invest.bsky.social is illuminating www.jci.org/articles/vie...

📣UM Liver Cancer Diagnosis and Treatment CME Course on March 15th 2025 in Southfield, MI: in person and online. Featuring UM faculty and Dr. Laura Kulik from Northwestern University. Registration here: umich.cloud-cme.com/course/cours...

🔥Nivolumab and Ipilimuma approved by EMA for advanced hepatocellular carcinoma 🔥 👇https://ec.europa.eu/health/documents/community-register/html/h1014.htm 👉great news for our patients > more options in 1st line 😅amazing: approval in 🇪🇺by EMA before 🇺🇸by FDA @myESMO @EASLedu @ILCAnews #livertwitter

How do we interpret and act on disparities in liver cancer outcomes ?? Expert editorial by @laurennephewmd.bsky.social journals.lww.com/hepcomm/full... #liversky 1/

The sickest patients are supposed to get priority for lifesaving transplants. But nearly 20% of the time, the American organ transplant system is skipping over hundreds or even thousands of people when it distributes kidneys, livers, lungs and hearts, a New York Times investigation found.

Every year I feel so fortunate to be part of this #LiverCancer community with these amazing friends who are true leaders sharing a common goal!! Amongst the beautiful chaos that is life, it’s important to find your passion and your people 💚. That’s a wrap @hcclive.bsky.social

Very sad news regarding Josh Levitsky. He was a seminal mentor for me and a great friend. He will be missed. Much love to his family and the Northwestern Transplant family.

Routine [18F]FCH and [18F]FDG PET-CT for tumour staging in all patients with a 1st diagnosis of hepatocellular carcinoma has limited clinical value Guidelines should continue to emphasise morphological imaging (eg MRI & CT) for staging #OncSky #MedSky @oncoalert.bsky.social @naultjc.bsky.social

This trial by @bloompringle.bsky.social will be seen as one of the most important in the field of FMT - 💩 transplant - for #cirrhosis Does the 💩 engraft? Does the 💩 work (improved barrier function)? This is why PPB is the future journals.lww.com/hepcomm/full... #liversky

Great review of hemangiomas, FNH, & more by @renumathyd.bsky.social! I encourage all learners to read the classic imaging features. ✅️Review the imaging yourself ✅️Follow up if >5cm ✅️Biopsy for atypical appearance journals.lww.com/hepcomm/fullte… @jhepatology.bsky.socia#Liverskyk#GITwitterer

BREAKING: 22 states sue NIH over Trump administration's new 15% cap on overhead for federal research grants. Suit filed federal court in Boston contends lifesaving research 'will grind to a halt' under the policy. Doc: storage.courtlistener.com/recap/gov.us...

BREAKING: rifaximin and simvastatin did not help people with decompensated cirrhosis Congratulations to Elisa Pose And congrats to @jama.com for getting this paper #liversky t.co/BuPL0mURhl

Can a pop up alert improve the quality of #cirrhosis care? Yes, #liversky Does improving adherence to quality measures improve outcomes? Not so fast New #medsky study: doi.org/10.14309/ajg... @amcollegegastro.bsky.social

How the environment impacts the liver And the risk of liver cancer Phenomenal review in Hep Comm: journals.lww.com/hepcomm/full... #liversky #medsky

NIH appears to have canceled/postponed all of its study sections—the independent review panels that approve federal grants for health research. Such grants fund the work/salaries of 300k people at more than 2,500 institutions

Hello #livertwitter friends- if you’re a liver cancer expert or want to be, please join us Feb 20-22 in Austin! We’d love to see you there! www.hcc-live.org @hcclive.bsky.social

New research - TACE combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study www.thelancet.com/journals/lan... @thelancet.bsky.social #MedSky #OncSky #LiverSky

Updated HCC management guidelines by @easlnews.bsky.social Must read 👇🏼👇🏼👇🏼 www.journal-of-hepatology.eu/article/S016... #Liversky

It's that time of the year again. In no particular order, I would like to share a few of #livertwitter in 2024 with #liversky These could be original research, guidance statement, position paper or editorial. This is def not an inclusive list. Feel free to add to the 🧵

NEW! #NatureReviewsGastroHep Review on current and emerging strategies for the prevention of hepatocellular carcinoma www.nature.com/articles/s41... 🔓 rdcu.be/d21qi #liversky #oncsky #livercancer #HCC

Congrats to our new GI and Hepatology Fellows!

Thought provoking presentation from Renu on the topic of hepatologists and HCC management #TLM24 @atoosarabiee.bsky.social we need to get Renu here on blue sky!

1/11 🤔Why does chronic hepatitis C infection "require" the intermediary of cirrhosis in order to cause hepatocellular carcinoma (HCC)? Chronic hepatitis B can "skip" this step, going directly from chronic infection to HCC. Why the difference?